Head to head
BPC-157 against Exosomes
Two things sold in the same clinics for the same promise. Exosomes have one randomised trial in 110 people with diabetic foot ulcers showing faster healing, and the field published a standards document because it could not consistently describe what it was studying, so almost nothing sold in a clinic resembles the studied preparation.
Column A
BPC-157Body Protection Compound 157
A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.
Column B
ExosomesExosomes and small extracellular vesicles
A randomised trial in 110 people with diabetic foot ulcers found faster healing. Almost nothing sold in a clinic resembles that preparation, and the field published a standards document because it could not consistently describe what it was studying.
Side by side, on the facts we can check
| Attribute | BPC-157 | Exosomes |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action | No exosome product is approved by the FDA for any indication. The agency has stated publicly that there are no approved exosome products and has acted against clinics marketing them, so anything sold in a clinic is unapproved regardless of how it is described. |
| Half-life | Under 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days. | Not meaningfully described. Systemically administered vesicles are cleared from circulation within minutes to hours, mostly by liver and spleen, which is one reason the strongest human evidence involves local application rather than infusion. |
| Molecular weight | 1,419.5 Da | Not applicable. These are vesicles rather than molecules, generally 30 to 150 nanometres in diameter. |
| Mechanism | In animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days. | Small extracellular vesicles, generally 30 to 150 nanometres, formed inside multivesicular bodies and released when those fuse with the cell membrane. They carry proteins, lipids, messenger RNA and microRNA, and they transfer that cargo to recipient cells, altering gene expression and behaviour. In the therapeutic context the cargo is the drug rather than the vesicle: the proposed effects on wound healing, inflammation and tissue repair come from what the vesicle is carrying, which depends on the source cell and how it was cultured. That is the crux of the characterisation problem. Two preparations of identical size and count can carry entirely different cargo, and nothing about the label tells you which you have. |
| Human studies cited | 5 | 1 |
| Legal status, US | Not approved; research use only | Investigational, not approved |
Frequently asked questions
What is the difference between BPC-157 and Exosomes?
BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. Exosomes: A randomised trial in 110 people with diabetic foot ulcers found faster healing. Almost nothing sold in a clinic resembles that preparation, and the field published a standards document because it could not consistently describe what it was studying.
Which has stronger research evidence, BPC-157 or Exosomes?
This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 1 of 4 for Exosomes. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are BPC-157 and Exosomes FDA-approved?
BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. Exosomes: No exosome product is approved by the FDA for any indication. The agency has stated publicly that there are no approved exosome products and has acted against clinics marketing them, so anything sold in a clinic is unapproved regardless of how it is described..
Related posts
Blog articles that cover BPC-157 or Exosomes, newest first.
- Healing & Recovery / Sep 8, 2026 / 9 minPeptides for Joint Pain: BPC-157, TB-500, Lorecivivint, Pentosan and Collagen Peptides, Evidence Tiered
- Healing & Recovery / Sep 8, 2026 / 8 minPeptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
- Safety / Sep 8, 2026 / 9 minPeptide Side Effects by Class: What Is Documented, What Is Anecdotal
- Safety / Sep 8, 2026 / 8 minHow to Read a Peptide Certificate of Analysis: HPLC Purity, Mass Spec Identity, Endotoxin, and Janoshik Verification
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.